Clinical Performance of the Elecsys CSF pTau₁₈₁/Aβ₄₂ Ratio for Concordance with Tau-PET in Two Independent Cohorts.

ABSTRACT:

Introduction

Amyloid- and tau-positron emission tomography (PET) are promising modalities for detecting pathological changes associated with Alzheimer's disease (AD); however, their application is limited. Although the use of cerebrospinal fluid (CSF) biomarkers as alternatives to amyloid-PET and tau-PET has been explored, no in vitro diagnostic-approved or commercial CSF biomarker assays are currently available for detecting tau pathology in clinical practice.

Methods

In this study, we determined and validated the optimal cutoff value for the ratio of tau phosphorylated at a threonine residue at position 181 (pTau₁₈₁) to β-amyloid(1-42) (Aβ₄₂) in CSF, measured with the Elecsys^® Phospho-Tau (181P) CSF and β-Amyloid(1-42) CSF immunoassays (Roc

SUBMITTER: Smith R 

PROVIDER: S-EPMC12450182 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature